Health-tech Area

Health-tech Area

  • Alzheimer’s prevention
  • Diabetes type II prevention
  • COVID19 antibody-based test

Alzheimer’s Prevention

Our Alzheimer’s prevention solution establishes a person’s expected propensity to develop the disease. We do this with Alz1, an accurate and reliable at-home test kit that measures an Alzheimer’s associated biomarker in the blood.

Non-bound copper is an expected Alzheimer’s associated biomarker and can contribute to the onset and progression of the disease. The normal range of non-bound copper in the blood is 0.5-1.9 μM per liter. Persons having a non-bound copper quantity above 1.9 μM have a three-time higher risk of developing dementia. Determining and regulating the non-bound copper level can contribute to reducing the risk of Alzheimer’s.

Buy your Alz1 and Alz1 Tab, a natural dietary supplement designed to reduce heavy metals content in the blood, on Alz1.com

buy now

Persons who have high levels of non-bound copper should consult with their physicians.

Diabetes Type II Prevention

Our Diabetes type II prevention solution establishes a person’s expected propensity to develop the disease. We do this with Dbt2, an accurate and reliable at-home test kit that measures a diabetes type II associated biomarker in the blood. Dbt2 will be available soon for commercialization.

COVID-19 antibody-based test

Antibody-based tests can tell whether someone has already had COVID-19. The Food and Drug Administration has issued its first authorization for a COVID-19 antibody test for emergency use on 1 April 2020. This most probably indicates that the FDA thinks the benefits of having such tests available to help in the response to the pandemic outweigh their known limits.

Please contact us for any further information on our product in your country at info@igeapharma.nl.